Business ❯ Biotechnology ❯ Pharmaceuticals

Drug Development

Clinical Trials Antibody-Drug Conjugates Obesity Treatments AI in Drug Discovery Autoimmune Diseases Clinical Research FDA Approvals Efficacy and Safety Results Celltrion Vepdegestrant

4 ARTICLES

5d ago

Akari’s AKTX-101 Shows Preclinical Synergy With KRAS Inhibitor as Stock Soars

If confirmed in people, the company’s RNA spliceosome‑modulating payload could change how KRAS‑mutant pancreatic cancers are targeted by ADC combinations.

6 ARTICLES

2w ago

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

4 ARTICLES

last mo.

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

5 ARTICLES

3mo ago

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

4 ARTICLES

3mo ago

Vertex Heads Into Feb. 12 Earnings With Cautious Market After Mixed Year

3 ARTICLES

3mo ago

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

4 ARTICLES

3mo ago

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

3 ARTICLES

4mo ago

Genentech Lifts Holly Springs Biomanufacturing Plan to $2 Billion, Over 500 Jobs

3 ARTICLES

4mo ago

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

8 ARTICLES

5mo ago

BioMarin to Acquire Amicus for $4.8 Billion in Cash

3 ARTICLES

5mo ago

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

3 ARTICLES

6mo ago

Phrontline Biopharma Raises $60 Million as Samsung Deepens ADC Push

4 ARTICLES

7mo ago

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

4 ARTICLES

7mo ago

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

3 ARTICLES

7mo ago

aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

4 ARTICLES

7mo ago

Drug Development

Akari’s AKTX-101 Shows Preclinical Synergy With KRAS Inhibitor as Stock Soars

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Vertex Heads Into Feb. 12 Earnings With Cautious Market After Mixed Year

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

Never miss stories about

Drug Development

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Genentech Lifts Holly Springs Biomanufacturing Plan to $2 Billion, Over 500 Jobs

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Phrontline Biopharma Raises $60 Million as Samsung Deepens ADC Push

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Never miss stories about

Drug Development